Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin 287 - Novo Nordisk

Next Previous
Drug Profile

Insulin 287 - Novo Nordisk

Alternative Names: 148-0287-A; Insulin-287; LAI-287; Long-acting basal insulin analogue; Long-acting-insulin-287; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI-287GT

Latest Information Update: 30 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 09 Dec 2019 Novo Nordisk completes a phase I trial in Type 1 diabetes mellitus in Japan (SC) (NCT03766854)
  • 10 Oct 2019 Novo Nordisk completes a phase I trial in Type 2 diabetes mellitus (Combination therapy, Monotherapy, Second-line therapy or greater) in Germany (SC, Injection) (NCT03789578)
  • 06 Sep 2019 Novo Nordisk completes a phase I trial in Type 2 diabetes mellitus in Germany (NCT03723785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top